Literature DB >> 30197683

MicroRNA-146a-5p enhances ginsenoside Rh2-induced anti-proliferation and the apoptosis of the human liver cancer cell line HepG2.

Weiwen Chen1,2, Shuai Chu1, Haixia Li1, Yurong Qiu1.   

Abstract

Liver cancer is one of the leading causes of malignancy-associated mortality worldwide and its clinical therapy remains very challenging. Ginsenoside Rh2 (Rh2) has been reported to have antitumor effects on some types of cancer, including liver cancer. However, its regulatory mechanism has not been extensively evaluated. In the present study, Rh2 increased the expression of microRNA (miR)-200b-5p, miR-224-3p and miR-146a-5p, and decreased the expression of miR-26b-3p and miR-29a-5p. Of the three upregulated miRs, miR-146a-5p exhibited the highest fold elevation. In accordance with a previous study, Rh2 effectively inhibited the survival of liver cancer cells in vitro and in a mouse model. In addition, it was observed that Rh2 markedly promoted liver cancer apoptosis and inhibited colony formation. Cell apoptosis and the inhibition of cell survival as well as colony formation induced by Rh2 were enhanced and weakened by miR-146a-5p overexpression and inhibition, respectively. The results of the present study provide further evidence of the antitumor effect of Rh2 in liver cancer and also demonstrate that this effect may be mediated via the regulation of miR-146a-5p expression in the liver cancer cell line HepG2. The results indicated that miR-146a-5p may be a promising regulatory factor in Rh2-mediated effects in liver cancer.

Entities:  

Keywords:  antitumor; ginsenoside Rh2; liver cancer; microRNA-146a-5p; promotion

Year:  2018        PMID: 30197683      PMCID: PMC6126334          DOI: 10.3892/ol.2018.9235

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  24 in total

1.  Ginsenoside Rh2 inhibits metastasis of glioblastoma multiforme through Akt-regulated MMP13.

Authors:  Ning Guan; Xiaochuan Huo; Zhenxing Zhang; Shoudan Zhang; Junsheng Luo; Wenshi Guo
Journal:  Tumour Biol       Date:  2015-04-03

2.  Hep G2 is a hepatoblastoma-derived cell line.

Authors:  Dolores López-Terrada; Sau Wai Cheung; Milton J Finegold; Barbara B Knowles
Journal:  Hum Pathol       Date:  2009-10       Impact factor: 3.466

3.  Antitumoral Activity of (20R)- and (20S)-Ginsenoside Rh2 on Transplanted Hepatocellular Carcinoma in Mice.

Authors:  Qun Lv; Na Rong; Li-Jia Liu; Xiao-Lin Xu; Jian-Ting Liu; Feng-Xie Jin; Chun-Mei Wang
Journal:  Planta Med       Date:  2016-05-10       Impact factor: 3.352

4.  Ginsenoside Rh2 differentially mediates microRNA expression to prevent chemoresistance of breast cancer.

Authors:  Xu Wen; He-Da Zhang; Li Zhao; Yu-Feng Yao; Jian-Hua Zhao; Jin-Hai Tang
Journal:  Asian Pac J Cancer Prev       Date:  2015

5.  MiR-146a suppresses hepatocellular carcinoma by downregulating TRAF6.

Authors:  Yong Zu; Yanhong Yang; Jiyun Zhu; Xiaobo Bo; Shuangxing Hou; Bo Zhang; Jiangfeng Qiu; Jing Zheng
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

6.  Ginsenoside Rh2 mediates changes in the microRNA expression profile of human non-small cell lung cancer A549 cells.

Authors:  In-Sook An; Sungkwan An; Ku Jung Kwon; Young Joo Kim; Seunghee Bae
Journal:  Oncol Rep       Date:  2012-11-14       Impact factor: 3.906

7.  Ginsenoside Rh2 inhibits invasiveness of glioblastoma through modulation of VEGF-A.

Authors:  Shaoyi Li; Yun Gao; Weining Ma; Tianci Cheng; Yunhui Liu
Journal:  Tumour Biol       Date:  2015-07-29

8.  Ginsenoside Rh2 inhibits hepatocellular carcinoma through β-catenin and autophagy.

Authors:  Zhiqing Yang; Tingting Zhao; Hongli Liu; Leida Zhang
Journal:  Sci Rep       Date:  2016-01-19       Impact factor: 4.379

Review 9.  Controversy about pharmacological modulation of Nrf2 for cancer therapy.

Authors:  Lidija Milkovic; Neven Zarkovic; Luciano Saso
Journal:  Redox Biol       Date:  2017-04-08       Impact factor: 11.799

10.  Inhibitory effects of ginsenoside Rh2 on tumor growth in nude mice bearing human ovarian cancer cells.

Authors:  H Nakata; Y Kikuchi; T Tode; J Hirata; T Kita; K Ishii; K Kudoh; I Nagata; N Shinomiya
Journal:  Jpn J Cancer Res       Date:  1998-07
View more
  4 in total

1.  Overexpression of miR-664 is associated with poor overall survival and accelerates cell proliferation, migration and invasion in hepatocellular carcinoma.

Authors:  Xianming Wang; Zhengtong Zhou; Tao Zhang; Minghai Wang; Rongwei Xu; Shiyong Qin; Shuguang Zhang
Journal:  Onco Targets Ther       Date:  2019-03-28       Impact factor: 4.147

2.  miR-26b-5p/TCF-4 Controls the Adipogenic Differentiation of Human Adipose-derived Mesenchymal Stem Cells.

Authors:  Yadong Luo; Huan Ji; Yan Cao; Xu Ding; Meng Li; Haiyang Song; Sheng Li; Chenxing WaTableng; Heming Wu; Jian Meng; Hongming Du
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

Review 3.  Targeting Epigenetic Regulatory Enzymes for Cancer Therapeutics: Novel Small-Molecule Epidrug Development.

Authors:  Ye Jin; Tianjia Liu; Haoming Luo; Yangyang Liu; Da Liu
Journal:  Front Oncol       Date:  2022-03-28       Impact factor: 6.244

Review 4.  Anticancer Activities of Ginsenosides, the Main Active Components of Ginseng.

Authors:  Heeok Hong; Delgerzul Baatar; Seong Gu Hwang
Journal:  Evid Based Complement Alternat Med       Date:  2021-02-03       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.